Table 2.

Secondary endpoints.

	Control	Nintedanib	P Value
	N = 30	N = 30
Ventilator-free days within 28 days	12 (0–17)	17 (0–21)	0.038
Percentage of high-attenuation areas on CT
Induction of mechanical ventilation (%)	29.1 (20.3–33.1)	30.8 (20.9–46.7)	0.651
Liberation from mechanical ventilation (%)	38.7 (20.9–45.6)	25.7 (9.4–34.6)	0.027
Gastrointestinal adverse events
Mild events	27 (90%)	25 (83.3%)	0.448
Moderate events	6 (20%)	9 (30%)	0.371
Severe events	3 (10%)	2 (6.7%)	0.640
Acute liver failure
Mild	20 (66.7%)	24 (80%)	0.243
Moderate	6 (20%)	11 (36.7%)	0.158
Severe	2 (6.7%)	2 (6.7%)	1.00

CT, computed tomography.